Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: A global developer, manufacturer, and marketer of specialized apparatus and scientific instruments for life science research (ADMET testing and molecular biology). The company operates primarily through its Apparatus and Instrumentation segment. The Capital Equipment Business segment was fully divested in 2008 and is reported as discontinued operations.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Revenues | $88.0 million | $83.4 million |
| Gross Profit | $42.2 million (47.9% margin) | $40.2 million (48.3% margin) |
| Operating Income | $8.5 million | $9.5 million |
| Net Income (Loss) | $1.7 million | $(1.4) million |
| Diluted EPS | $0.05 | $(0.04) |
| Cash and Equivalents | $13.7 million | $17.9 million |
| Working Capital | $32.2 million | $38.0 million |
| Long-Term Debt | $0.1 million | $5.6 million |
| Stockholders' Equity | $66.7 million | $74.1 million |
Note: Net income includes a $3.3 million loss on the disposition of discontinued operations (Union Biometrica) and a $0.5 million operating loss from discontinued operations.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5.6% to $88.0 million. This was driven by the full-year inclusion of the Panlab subsidiary (acquired late 2007), which added $6.8 million in revenue. Organic growth was offset by a $3.0 million negative impact from the strengthening U.S. dollar.
- Profitability: Operating income decreased 11% to $8.5 million. Gross margin declined slightly to 47.9% due to inventory write-downs related to restructuring and the lower-margin mix of the Panlab acquisition.
- Discontinued Operations: The company completed the sale of its remaining Capital Equipment assets (Union Biometrica) in September 2008, recording a $3.3 million loss on the sale. This contrasts with 2007, which included a $3.1 million loss on the sale of Genomic Solutions.
- Debt Reduction: The company repaid its $5.5 million balance on its revolving credit facility during 2008, ending the year with no borrowings under the facility. Long-term debt consists primarily of $1.4 million in notes payable from the Panlab acquisition.
- Foreign Exchange: The strengthening U.S. dollar reduced reported revenues by $3.0 million and expenses by $2.6 million. It also resulted in an $8.9 million reduction in Stockholders' Equity due to the translation of foreign net assets.
Guidance, Outlook, and Risks
- 2009 Outlook: Management expects organic growth in the "low single digit range" for 2009. Initiatives include launching a new Biochrom US subsidiary, full-year impact of new catalogs, and continued operational consolidation.
- Restructuring: The company anticipates incurring approximately $0.5 million in restructuring costs in the first half of 2009 related to the consolidation of electrophoresis operations, with expected savings of $0.005 per share on a full-year basis.
- Capital Resources: The company has a $20.0 million credit facility expiring December 1, 2009. Management is negotiating a renewal but notes that prevailing interest rates may be 0.5% higher than current rates due to credit market conditions.
- Key Risks:
- Concentration: GE Healthcare accounted for 15% of 2008 revenues. The distribution agreement expires in 2012 but can be terminated with notice.
- Acquisition Strategy: Future growth relies on acquisitions, which may be constrained by credit market volatility and the need for additional capital.
- Goodwill Impairment: Goodwill and intangible assets represent 42% of total assets ($33.8 million). A decline in stock price or cash flow projections could trigger impairment charges.
- Foreign Currency: Approximately 61% of revenues are from non-U.S. operations. Continued strengthening of the U.S. dollar against the Euro and British Pound would negatively impact earnings.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the extent to which the $3.3 million loss on the Union Biometrica sale impacts the assessment of core operating performance.
- GE Healthcare Dependency: Review the terms of the distribution agreements with GE Healthcare (15% of revenue) and the risks associated with potential non-renewal or termination.
- Credit Facility Renewal: Monitor the status of the $20 million credit facility renewal, given the expiration date of December 1, 2009, and current credit market conditions.
- Foreign Exchange Sensitivity: Assess the impact of the strong U.S. dollar on future revenue and earnings, as 61% of revenue is international.
- Stock Repurchase Program: Note that the company repurchased 834,265 shares in Q4 2008, with $7.4 million remaining under the $10 million authorization.